Subtherapeutic Target Attainment of Intermittent Vancomycin in a Paediatric Burn Patient: A Case Report.
DOI:
https://doi.org/10.70672/pcqvfm38Keywords:
Burn, paediatric, pharmacokinetics, therapeutic drug monitoring, vancomycin.Abstract
Vancomycin pharmacokinetics in pediatric burn patients can be significantly altered compared to non-burned children due to the physiological changes caused by burn injuries, especially in the hypermetabolic and hyperdynamic phases. Subtherapeutic serum vancomycin concentrations and the consequent need for drastic modification of vancomycin dosage regimen has been reported. This is a case report of a paediatric patient with a Total Body Surface Area (TBSA) of 50 percent with subtherapeutic vancomycin target attainment even with a total daily dose of more than 80 mg/kg/day and the use of prolonged vancomycin infusion.
References
[1]. World Health Organization. Burns [Internet]. WHO. World Health Organization: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/burns
[2]. Collier ZJ, McCool K, Magee WP, Potokar T, Gillenwater J. 58 Burn Injuries in Asia: A Global Burden of Disease Study. Journal of Burn Care & Research. 2022 Mar 23;43(Supplement_1):S40–1.
[3]. Low CX, Kok YQ, Loo XS, Ngim CF, Lim RZM, Quah SY. Three-year epidemiology of hospitalised paediatric burn patients in a Malaysian tertiary hospital 2016–2018. Med J Malaysia. 2023 Sep;78(5):661-668.
[4]. Christie M, Theunis Avenant, Masindi Nembudani, Anelisa Mnqandi, Muller C, Villiers M de, et al. Insights into bloodstream infections in South African paediatric burn patients: implications for antimicrobial stewardship. BMC Infectious Diseases. 2025 Mar 14;25(1).
[5]. Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK. Serum Vancomycin Levels Resulting From Continuous or Intermittent Infusion in Critically Ill Burn Patients With or Without Continuous Renal Replacement Therapy. Journal of Burn Care & Research. 2012;33(6):e254–62.
[6]. Murphy JE, American Society of Health-System Pharmacists. Clinical pharmacokinetics. Bethesda, Md: American Society of Health-System Pharmacists; 2017.
[7]. Patel S, Preuss CV, Bernice F. Vancomycin [Internet]. National Library of Medicine. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459263/
[8]. Cox IR. Pharmacokinetics in Patients with Burns. Journal of Pharmacy Practice and Research. 2005 Mar;35(1):53–5.
[9]. Carter BL, Damer KM, Walroth TA, Buening NR, Foster DR, Sood R. A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients. Journal of Burn Care & Research: Official Publication of the American Burn Association [Internet]. 2015 [cited 2023 Aug 22];36(6):641–50. Available from: https://pubmed.ncbi.nlm.nih.gov/25423436/
[10]. Gomez DS, Campos EV, de Azevedo RP, Silva-Jr JM da, Ferreira MC, Sanches-Giraud C, et al. Individualised Vancomycin doses for paediatric burn patients to achieve PK/PD targets. Burns. 2013 May;39(3):445–50.
[11]. Zakaria Z, Fong A, Badhan R. Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability. Pharmaceuticals. 2018 Jul 26;11(3):74.
[12]. Ang GY, Yu CY, Subramaniam V, Abdul Khalid MIH, Tuan Abdu Aziz TA, Johari James R, et al. Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data. Vrana KE, editor. PLOS ONE. 2016 Oct 31;11(10):e0164169.
[13]. Rhoney DH, Metzger SA, Nelson NR. Scoping review of augmented renal clearance in critically ill pediatric patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2021 Aug 30;41(10):851–63.
[14]. Bailie GR, Ackerman BH, Fischer J, Solem LD, Rotschafer JC. Increased Vancomycin Dosage Requirements in Young Burn Patients. Journal of Burn Care & Rehabilitation. 1984 Sep 1;5(5):376–8.
[15]. A.M Dell’Aquila, McCulloch JA, E.M Mamizuka, Santos SRCJ, Pereira CAP. Serum levels of Vancomycin should be monitored in burn patients. Burns. 2004 Apr 23;30(4):386–7.
[16]. Dolton M, Xu H, Cheong E, Maitz P, Kennedy P, Gottlieb T, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns. 2010 Jun;36(4):469–76.
[17]. Shi Y, Yin Z, Zhang Q, Yi L, Dou Y. Factors influencing Vancomycin trough concentration in burn patients: a single center retrospective study. Frontiers in Pharmacology [Internet]. 2024 Dec 12 [cited 2025 Jul 10];15. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11672795/
[18]. Garrelts JC, Peterie JD. Altered Vancomycin dose vs. serum concentration relationship in burn patients. Clinical Pharmacology & Therapeutics [Internet]. 1988 Jul 1 [cited 2024 Sep 8];44(1):9–13. Available from: https://pubmed.ncbi.nlm.nih.gov/3292106/
[19]. Li J, Zhu Y, Zhu X, Kong X. Association between prolonged Vancomycin infusion and trough concentrations in children. Retrospective study. Archivos Argentinos de Pediatría. 2024;122(6):e07.
[20]. Junker A, Howe Z, Schneider JG, Bhumbra S, Kussin ML. Continuous Infusion Vancomycin Dosing and Area Under the Curve Target Attainment in a Freestanding Children’s Hospital. Journal of the Pediatric Infectious Diseases Society. 2024 Oct;13(Supplement_3):S12–3.
[21]. Girand HL. Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence. 2020 Apr 1 [cited 2023 Jul 10];25(3):198–214. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134591/
[22]. Chuphan C, Sukarnjanaset W, Puthanakit T, Wattanavijitkul T. Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function. The Journal of Pediatric Pharmacology and Therapeutics. 2022 May 1;27(5):419–27.
[23]. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin. Antimicrobial Agents and Chemotherapy. 2008 Jun 30;52(9):3315–20.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medicine & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Engineering Technology (JET) is an open-access journal that follows the Creative Commons Attribution-Non-commercial 4.0 International License (CC BY-NC 4.0)
